LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Lista de Ações・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Fechado

SetorSaúde

56.54 -0.72

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

56.36

Máximo

57.32

Indicadores-chave
By Trading Economics
Rendimento	1.6B 2.7B
Vendas	-1B 11B
P/E Médio do Setor	16.073 49.8
EPS	1.58
Rendimento de Dividendos	4.29
Margem de lucro	23.309
Funcionários	32,500
EBITDA	1.5B 3.7B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+12.04% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	4.29% 2.25%
Próximos Ganhos	30 de jul. de 2026
Próxima data de dividendos	31 de jul. de 2026
Próxima data de ex-dividendo	2 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-817M 117B
Abertura anterior	57.26
Fecho anterior	56.54

Sentimento de Notícias

By Acuity

35%

65%

110 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

N/A / 50.57 Suporte e Resistência

Bristol-Myers Squibb Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 11:14 UTC

Ganhos

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

5 de mai. de 2026, 18:12 UTC

Ganhos

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 de mai. de 2026, 13:54 UTC

Ganhos

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 de abr. de 2026, 10:59 UTC

Ganhos

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14 de abr. de 2026, 14:13 UTC

Ganhos

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 de abr. de 2026, 12:57 UTC

Ganhos

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 de abr. de 2026, 11:19 UTC

Ganhos

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 de abr. de 2026, 10:34 UTC

Ganhos

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13 de abr. de 2026, 21:23 UTC

Ganhos

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

6 de fev. de 2026, 12:35 UTC

Ganhos

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

5 de fev. de 2026, 15:25 UTC

Ganhos

Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. -- Barrons.com

5 de fev. de 2026, 13:10 UTC

Ganhos

Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors. -- Barrons.com

Comparação entre Pares

Variação de preço

Bristol-Myers Squibb Co. Previsão

Preço-alvo

By TipRanks

12.04% parte superior

Previsão para 12 meses

Média 64.29 USD 12.04%

Máximo 75 USD

Mínimo 54 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Bristol-Myers Squibb Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

Comprar

Manter

Vender

Com base em 18 analistas que deram avaliações de ações para Bristol-Myers Squibb Co. - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

N/A / 50.57Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimento

By Acuity

110 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.